Zealand Pharma Logo

Zealand Pharma

A biotechnology company developing peptide-based medicines for metabolic and rare diseases.

ZEAL | CO

Overview

Corporate Details

ISIN(s):
DK0060257814 (+2 more)
LEI:
549300ITBB1ULBL4CZ12
Country:
Denmark
Address:
Sydmarken 11, 2860 Søborg

Description

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-17 17:05 English 5.6 KB
2025-10-17 17:05 English 553.9 KB
2025-10-17 17:05 English 377.4 KB
2025-09-30 17:05 English 5.6 KB
2025-09-11 22:00 English 5.9 KB
2025-08-20 22:00 English 5.6 KB
2025-08-20 22:00 English 550.7 KB
2025-08-20 22:00 English 367.5 KB
2025-08-14 07:00 English 25.7 KB
2025-08-14 07:00 English 891.1 KB
2025-07-18 18:30 English 301.0 KB
2025-07-18 18:30 English 5.6 KB
2025-07-18 18:30 English 516.4 KB
2025-06-30 17:05 English 5.6 KB
2025-06-18 17:29 English 14.1 KB

Automate Your Workflow. Get a real-time feed of all Zealand Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zealand Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zealand Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Adaptive Biotechnologies Corp Logo
Decodes the adaptive immune system to develop products for diagnosing and treating disease.
United States of America
ADPT
Adeia Inc. Logo
R&D company that licenses IP for the media, entertainment, and semiconductor industries.
United States of America
ADEA
Aditxt, Inc. Logo
Acquires, develops, and deploys health technologies to address major health challenges.
United States of America
ADTX
Advanced Biomed Inc. Logo
Develops microfluidic biochip diagnostic systems for precision oncology.
United States of America
ADVB
AIM ImmunoTech Inc. Logo
Immuno-pharma company developing therapeutics for oncology, immune, and viral diseases.
United States of America
AIM
Ainos, Inc. Logo
Develops AI-driven diagnostics, immune therapeutics, and telehealth POCT devices.
United States of America
AIMD
Akero Therapeutics, Inc. Logo
Clinical-stage company developing treatments for serious metabolic diseases like MASH.
United States of America
AKRO
Aladdin Healthcare Technologies SE Logo
Develops AI-powered tools for drug discovery and diagnostics for age-related conditions.
Germany
NMI
Alaunos Therapeutics, Inc. Logo
Clinical-stage immuno-oncology company developing TCR-T cell therapies for solid tumors.
United States of America
TCRT
Aligos Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapeutics for liver and viral diseases.
United States of America
ALGS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.